11C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 2, 2013, Pages 149-155

  Ceci, Francesco ^a   Castellucci, Paolo ^a   Mamede, Marcelo ^b   Schiavina, Riccardo ^a   Rubello, Domenico ^c   Fuccio, Chiara ^d   Ambrosini, Valentina ^a   Boschi, Stefano ^a   Martorana, Giuseppe ^a   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^d IRCCS   (Italy)

Author keywords

11C Choline; Biochemical relapse, triggers PSA; Hormone therapy resistance; PET CT; Prostate cancer; PSA kinetics; Radical prostatectomy

Indexed keywords

BICALUTAMIDE; CHOLINE C 11; CYPROTERONE; DUTASTERIDE; ESTRAMUSTINE; FLUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN; TRIPTORELIN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; FOLLOW UP; HORMONE RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPHADENECTOMY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; TRANSRECTAL ULTRASONOGRAPHY; WHOLE BODY PET;

AGED; AGED, 80 AND OVER; BIOPSY; CARBON ISOTOPES; CHOLINE; HORMONES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KINETICS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 84874112814     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2272-z     Document Type: Article

References (26)

1. Kataja VV, Bergh J. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann Oncol. 2005;16 Suppl 1:i34-6.
2. Freedland SJ, Presti Jr JC, Amling CL, Aronson WJ, Dorey F, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61:736-41.
3. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517-23.
4. Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(20):380-5.
5. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001;76:576-81.
6. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology. 2004;233:379-85.
7. Coakley FV, Teh HS, Qayyum A, Swanson MG, Lu Y, Roach 3rd M, et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology. 2004;233:441-8.
8. Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008;179:906-10.
9. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Freedland SJ, Dekernion JB, et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol. 2004;171:2260-4.
10. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. Guidelines on prostate cancer. Eur Urol. 2011;59(1):61-71.
11. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, et al. 18Ffluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33:1387-98.
12. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of 18F-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:253-63.
13. Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, et al. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:1106-16.
14. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394-400.
15. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of 11Ccholine-positron emission tomography for re-staging prostate cancer: a comparison with 18Ffluorodeoxyglucose-positron emission tomography. J Urol. 2003;169:1337-40.
16. Pascali C, Bogni A, Itawa R, Cambiè M, Bombardieri E. [11C]Methylation on a C18 Sep-Pak cartridge: a convenient way to produce N-methyl-11Ccholine. J Labelled Comp Radiopharm. 2000;49:195-203.
17. Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol. 2003;170:2274-8.
18. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990-5.
19. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of 11Ccholine-PET/TC depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18-23.
20. Soyka JD, Muster MA, Schmid DT, Schick U, Miralbell R. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2012;39:936-43.
21. DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001;61:110-7.
22. De Waele A, Van Binnebeek S, Mottaghy FM. Response assessment of hormonal therapy in prostate cancer by [11C]choline PET/CT. Clin Nucl Med. 2010;35:701-3.
23. Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging. 2008;35:1065-73.
24. Fuccio C, Schiavina R, Castellucci P, Rubello D, Martorana G, Celli M, et al. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging. 2011;38:1985-9.
25. Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:301-9.
26. Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, et al. Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5ng/ml? Eur J Nucl Med Mol Imaging. 2011;38:55-63.